Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL3990044

RELATLIMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL3990044
Name RELATLIMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

BMS-986016 Relatlimab Relatlimab component of bms-986213 Relatlimab component of opdualag -rmbw Relatlimab rmbw Relatlimab-rmbw
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
6
Known Names
20
Indications
1
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2022
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

First in Class
USAN Stem -mab
USAN Year 2017

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Lymphocyte activation gene 3 protein inhibitor INHIBITOR Lymphocyte activation gene 3 protein ✓ ✓

Indications

Colorectal Neoplasms Colorectal Neoplasms Colorectal Neoplasms Melanoma Melanoma Melanoma Carcinoma, Basal Cell Carcinoma, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Squamous Cell Chordoma Colonic Neoplasms Leukemia, Myeloid, Acute Liver Neoplasms Multiple Myeloma Nasopharyngeal Carcinoma Neoplasms

Data from ChEMBL 36 via Core Engine